Guided Therapeutics (GTHP) Return on Sales (2010 - 2025)

Guided Therapeutics has disclosed Return on Sales across 16 years of filings, most recently posting 0.02% for Q4 2025.

• Return on Sales for Q4 2025 came in at 0.02%, up 650.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.04% (up 341.0% YoY), and the FY2025 annual result was 0.04%, up 341.0% from the prior year.
• Return on Sales came in at 0.02% for Q4 2025 at Guided Therapeutics, up from 0.12% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.04% in Q3 2021 to a low of 24.42% in Q1 2025.
• The 5-year median for Return on Sales is 0.57% (2024), against an average of 2.5%.
• Peak annual rise in Return on Sales reached 650 bps in 2025, while the deepest fall reached 2375 bps in 2025.
• Guided Therapeutics' Return on Sales stood at 0.07% in 2021, then sank by 4414 bps to 3.34% in 2022, then surged by 96 bps to 0.12% in 2023, then plunged by 5305 bps to 6.52% in 2024, then jumped by 100 bps to 0.02% in 2025.
• The last three Return on Sales figures came in at 0.02% (Q4 2025), 0.12% (Q3 2025), and 0.07% (Q2 2025), per Business Quant data.